VRDN · Viridian Therapeutics Inc
United States · RS rating 86 · As of 2026-11-03
| Price | 25.15 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 86 / 97 / 89 / 57 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 33 / 36 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -217.7% |
| Sales growth Q/Q | -99.8% |
| Distance from 52-week high | +25.6% |
| Market cap (USD) | $1.5B |